pp-008 Tablets 10 mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Comments
A sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days